Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

179 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The T and B cells repertoire diversity represent one of the immune defence level which controls the integrity of the organism and determines its ability to recognize and control infectious attacks and development of tumours. The study of the lymphocytes TCR and BCR diversity could permit to better understand how lymphopenia act on overall survival and to improve detection of high risk patients who could benefit of adapted therapies for better care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy

NCT01513408

Breast Cancer

ACTIVE_NOT_RECRUITING NA

Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer

NCT04645849

Breast Cancer

UNKNOWN

Tracking Triple-negative Breast Cancer Evolution Through Therapy

NCT03077776

Triple-Negative Breast Neoplasm

ACTIVE_NOT_RECRUITING NA

Multidisciplinary Approach to Breast Cancer Through the Study of Altered Transcriptomic and Immune Accompanied by the Identification of Extractable Markers From the Radiodiagnostic Bioimaging

NCT05809128

Breast Cancer Patients

UNKNOWN

Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

NCT02530008

Women With Suspected or Confirmed Recurrent Breast Cancer

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The therapeutic management recommendations of patients with metastatic cancer offer standard treatment in specific situations. But, there is always a subgroup of patients who do not benefit from treatment and which has a very low survival. The risk of death for patients is very variable depending on the initial cancer site, tumor aggressiveness and chemosensitivity of tumours.

It's therefore important to have relevant prognostic tools to predict such an excess of relative toxicity or drug resistance. Simple prognostic factors for survival as the performance status (PS) have already been highlighted in several studies. Thus, the possibility to identify a group of patients with a higher risk of mortality could be of major interest for clinicians. In fact such stratification will allow:

* To limit this risk by adjusting the therapy and/or associated treatments (antibiotic prophylaxis, dose reduction ...),
* To develop protocols for testing innovative strategies specific to this high risk population.

The objectives of these innovative protocols would be designed to correct lymphodivpenia.

The main objective is to show that T divpenia (low TCR combinatorial diversity \<30%) is a risk factor for early death after chemotherapy (early death: any death occurring within 3 months (lung cancer) or within 6 months (breast cancer) after the start of chemotherapy).

The secondary objectives are:

* To establish that the divpenia factor is independent of clinical and biological prognostic factors (PS, LDH, haemoglobin, lymphopenia or ANC) to predict a early death,
* To establish that the prognostic score NDL which will combine in a two-dimensional graph the CD4 count or total lymphocytes count and TCR repertoire diversity will allow a better stratification of lympho-divpenic patients who will benefit from more appropriate treatments,
* To characterize other circulating markers this could improve the identification of the early death risk (phenotypic markers, cytokines ...) in combination with the previous settings.

Prognostic models have been established in many tumor types at the initial stage or at time of the relapse (breast and lung cancers ...). It seems necessary to highlight other clinical and biological prognostic factors that would estimate a lower survival at 6 months, whatever the nature or the original site of the tumour.

The strong prognostic value of lymphopenia in the early death after chemotherapy or hematologic toxicity of chemotherapy has recently been established in several tumor models. 25% of patients with metastatic solid cancers have a systemic immune dysfunction.

Further analysis incorporating prior any treatment (D0) a systematic phenotypic analysis of lymphocyte subpopulations in the patients' blood showed that a significant reduction in the absolute number of peripheral CD4+ T cells (\<450/μl) was an independent factor risk of early death and febrile neutropenia in patients with solid cancers of different origin (lymphoma, myeloma, sarcoma, breast cancer) treated with chemotherapy.

However, early death remains rare events and a more recent study has established that a lymphopenia (\<1000 lymphocytes/µl) was an independent prognostic factor for overall survival in patients with solid tumours.

Recent studies have shown the importance of combinatorial diversity of T and B lymphocytes repertoire (TCR/BCR) in the efficiency of the immune response against infection.

A preliminary analysis of TCR repertoire diversity, in a retrospective cohort of patients with metastatic breast cancer, demonstrated the independent predictive value of divpenia for overall survival in these patients. This research has demonstrated that patients with cancer had a very large disparity in immune TCR diversity and that it was not always correlated with lymphocyte count.

These preliminary data show that the discriminating power of TCR diversity is greater than the measurement of cell count. The combined analysis of these data in a NDL® graph may help to better discriminate patients at risk for which it is necessary to develop new therapeutic strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast cancer

Metastatic breast cancer

Breast cancer cohort

Intervention Type BIOLOGICAL

Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.

For each patient, the following analyses is performed:

* The analysis of TCR and BCR repertoire diversity,
* The phenotypic analysis of immune subpopulations,
* The analysis of the global lymphopenia or subpopulations T,
* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.

Lung cancer

Metastatic lung cancer

Lung cancer cohort

Intervention Type BIOLOGICAL

Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.

For each patient, the following analyses is performed:

* The analysis of TCR and BCR repertoire diversity,
* The phenotypic analysis of immune subpopulations,
* The analysis of the global lymphopenia or subpopulations T,
* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Breast cancer cohort

Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.

For each patient, the following analyses is performed:

* The analysis of TCR and BCR repertoire diversity,
* The phenotypic analysis of immune subpopulations,
* The analysis of the global lymphopenia or subpopulations T,
* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.

Intervention Type BIOLOGICAL

Lung cancer cohort

Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.

For each patient, the following analyses is performed:

* The analysis of TCR and BCR repertoire diversity,
* The phenotypic analysis of immune subpopulations,
* The analysis of the global lymphopenia or subpopulations T,
* The analyses by multiplex assay of a large panel of plasma cytokines and chemokines.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old,
* Patients with an histologically proven, inoperable breast or lung tumour,
* Metastatic disease before the start of any chemotherapy,
* Signed written informed consent form,
* Covered by a medical insurance,
* Patient accepting the conservation of biological samples,
* Locally advanced incurable disease (only breast tumour).

Exclusion Criteria

* Hematological tumour,
* Auto-immune disease (including HIV-positive - AIDS stage) or patients with immunosuppressive therapy,
* Metastatic disease that had progressed after a first line chemotherapy,
* Pregnant or lactating female or female of child-bearing potential not employing adequate contraception,
* Patient deprived of liberty by a judicial or administrative,
* Adult protected by law.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No